Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DKK1 | O94907 | 3/20 | 0.63 |
| ▸ | RAD52 | P43351 | 1/20 | 0.58 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3651842 | 0.95 | DKK1 (0.69) | DKK1RAD52CCNT1CCNA2CDK2 | |
| SCHEMBL3644943 | 0.91 | DKK1 (0.74) | DKK1RAD52CCNT1CCNA2CDK2 | |
| SCHEMBL3650801 | 0.88 | DKK1 (0.74) | DKK1RAD52STK17ACCNT1CCNA2 | |
| SCHEMBL3647434 | 0.87 | DKK1 (0.72) | DKK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL3649376 | 0.87 | DKK1 (0.72) | DKK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL3648290 | 0.86 | DKK1 (0.74) | DKK1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL4522527 | 0.85 | DKK1 (0.60) | DKK1RAD52 | |
| SCHEMBL3651081 | 0.84 | DKK1 (0.62) | DKK1RAD52CCNT1CCNA2CDK2 | |
| SCHEMBL4522804 | 0.83 | DKK1 (0.60) | DKK1CDK2 | |
| SCHEMBL4535074 | 0.83 | DKK1 (0.57) | DKK1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | DKK1 9/4885RAD52 880/4885STK17A 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.